SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MEDX ... anybody following?
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2240 62 0 MEDX
Emcee:  Ed Offstein Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2090Antibody treatment controls AIDS in monkeys Keith Alcorn, Thursday, December 11,Icebrg-12/11/2008
2089The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Icebrg-12/6/2008
2088High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during AcutIcebrg-12/4/2008
2087Additional immune checkpoints in prostate cancer: PD-1 and LAG-3 Wednesday, 3 DIcebrg-12/4/2008
2086PDUFA dates J&J - copied from the Y! board. I just posted a new article andIcebrg-11/30/2008
2085>>Not very much. It is supposed to be 50 mUSD at peak sales of 1,8 billionnigel bates-11/28/2008
2084S-P says prospects are good for "best pipeline in history" 25 NovemberIcebrg-11/27/2008
2083<i>What is Medarex's royalty rate on this product?</i> Not veryIcebrg-11/26/2008
2082What is Medarex's royalty rate on this product?JamesK-11/26/2008
2081Janssen-Cilag: ustekinumab moves closer to psoriasis market leadership 24th NoveIcebrg-11/26/2008
2080Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1Icebrg-11/24/2008
2079New Biologic Ustekinumab Receives Positive Opinion From European Regulatory AuthIcebrg-11/21/2008
2078Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma. J Clin OnIcebrg-11/20/2008
2077ACZ885 (canakinumab) is a new treatment for a group of rare, but potentially lifIcebrg-11/19/2008
2076Celldex Announces Licensing Agreement for Novel Cancer Antibody Program Tuesday Icebrg-11/11/2008
2075Medarex Receives Milestone Payment for Investigational Antibody Targeting IntegrIcebrg-11/5/2008
2074Medarex and Massachusetts Biologic Laboratories Announce Primary Objective AchieIcebrg-11/3/2008
2073Efficacy and safety of golimumab in patients with ankylosing spondylitis: ResultIcebrg-11/2/2008
2072CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hIcebrg-11/2/2008
2071Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Vatnsaf-10/28/2008
2070<i>Nothing new, but a nice collection of information from PD-1 studies thetnsaf110/20/2008
2069GENMAB REPORTS RESULTS OF PORTFOLIO REVIEW Zanolimumab Program to Be DiscontinueIcebrg-10/8/2008
2068Celldex Receives $10 Million Milestone Payment Thursday October 2, 8:00 am ET NIcebrg-10/2/2008
2067From a treasurer's position at Medarex to becoming the CEO of Avant/Celldex Icebrg-9/30/2008
2066Selective expansion of a subset of exhausted CD8 T cells by {alpha}PD-L1 blockadIcebrg-9/25/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News